ATM rs1801516: Genetics and Radiosensitivity
The rs1801516 single nucleotide polymorphism is a missense variant (p.Asp1853Asn) located in the ATM gene, an essential regulator of cellular responses to DNA double-strand breaks. Research in radiogenomics associates the minor A allele with a modest increase in the risk of normal tissue toxicity following radiation therapy. However, clinical evidence remains limited and mixed regarding broader cancer susceptibility, meaning it cannot currently guide standalone medical choices.
What each genotype means
| Genotype | What the research suggests | Reading |
|---|---|---|
| GG | You carry two copies of the ancestral G allele, which encodes the conventional aspartic acid at position 1853. This is the most prevalent genotype across worldwide populations and represents baseline cellular DNA repair dynamics. It is not associated with an elevated risk of radiation-induced normal tissue toxicity in published radiogenomics research. | Informational |
| GA | You carry one copy of the ancestral G allele and one copy of the variant A allele (p.Asp1853Asn). Research indicates a slight, modest elevation in the statistical likelihood of experiencing acute normal tissue toxicity if exposed to therapeutic radiation. However, overall cancer risk is generally considered comparable to baseline, and this genotype carries no established medical requirement to alter care. | Higher attention |
| AA | You carry two copies of the variant A allele, producing an asparagine substitution at codon 1853 on both chromosomes. While associated in cohort studies with an incremental increase in tissue sensitivity following therapeutic ionizing radiation, the genotype does not indicate high-penetrance disease or an impaired ability to safely undergo essential diagnostic imaging. | Higher attention |
Molecular Profile and Genetic Identity
The single nucleotide polymorphism (SNP) designated rs1801516 is situated on chromosome 11 within exon 37 of the ATM (ATM serine/threonine kinase) gene. In standard genomic reference coordinates, it represents a transition from guanine to adenine at coding nucleotide 5557 (c.5557G>A). This alteration results in a missense amino acid substitution where aspartic acid is replaced by asparagine at codon 1853 (p.Asp1853Asn). Although this residue does not lie within a known catalytic kinase domain, the region around codon 1853 exhibits strong evolutionary conservation among vertebrates, suggesting structural or regulatory importance. In public repositories like ClinVar, rs1801516 is widely classified as a benign or likely benign variant concerning classic monogenic Ataxia-Telangiectasia, though it remains actively cataloged in pharmacogenomic research for its subtle modifier effects on ionizing radiation response.
The Biological Role of the ATM Kinase
The ATM gene encodes a critical high-molecular-weight serine/threonine kinase that functions as a master orchestrator of the DNA damage response (DDR). When ionizing radiation or chemotherapeutic agents cause DNA double-strand breaks, the ATM kinase is rapidly recruited and activated by autophosphorylation. Activated ATM phosphorylates numerous downstream target proteins, including p53, CHEK2, and BRCA1, initiating essential cellular checkpoints that temporarily halt the cell cycle for repair or trigger programmed cell death (apoptosis) if the genetic damage is irreparable. Because of ATM's central coordinating position in preserving chromosomal integrity, subtle functional shifts or polymorphic variations in the gene can theoretically alter how effectively healthy host tissues tolerate cytotoxic insults such as therapeutic radiation.
Radiation Toxicity and Cancer Risk Evidence
The primary clinical interest in rs1801516 stems from the field of radiogenomics. Large-scale individual patient data meta-analyses have found that carriers of the minor A allele (encoding asparagine) face a modest, statistically significant increase in the risk of acute and late radiation-induced normal tissue toxicity, such as dermatitis and mucosal reactions, with odds ratios around 1.2 to 1.5. In contrast, extensive meta-analyses evaluating rs1801516 as a primary risk factor for baseline cancer development have yielded largely negative or inconsistent results. Broad genome-wide association studies do not identify rs1801516 as an independent primary oncogenic driver for major malignancies such as breast cancer, emphasizing that its potential biological impact is largely contextual and unconfirmed as a standalone clinical hazard.
Clinical Interpretation and Limitations
Despite measurable statistical associations in large research cohorts, rs1801516 is classified as having limited clinical actionability. It is critical for individuals to understand that carrying one or two copies of the minor A allele does not signify a diagnosis of Ataxia-Telangiectasia, nor does it guarantee heightened adverse reactions to radiation therapy or chemotherapy. Current professional oncology guidelines, including those from radiation oncology societies, do not recommend altering radiation dosages, withholding indicated cancer treatments, or modifying diagnostic radiography schedules based on rs1801516 genotype status alone. Because individual tissue tolerance depends on anatomical, mechanical, and multifactorial biological traits, this genetic result should be viewed as an exploratory biomarker rather than an absolute predictive tool.
How common is this variant?
The minor A allele occurs at an estimated frequency of 15% to 22% in populations of European ancestry, whereas it is markedly less frequent in East Asian cohorts, where allele frequencies are typically around 4%.
Frequently asked questions
Does having the ATM rs1801516 variant mean I have Ataxia-Telangiectasia?
No. Ataxia-Telangiectasia is a rare, severe recessive condition caused by high-impact, loss-of-function pathogenic mutations on both copies of the ATM gene. Variant rs1801516 is a common missense variation that is considered benign regarding this syndrome and does not cause classic Ataxia-Telangiectasia.
Should I avoid necessary radiation therapy if I carry the A allele?
No, you should never refuse or delay recommended radiation therapy based on this genotype alone. Although research shows a slight statistical correlation with normal tissue reactions, the effect size is modest, and clinical guidelines strictly advise against modifying radiation plans without a validated clinical indication. Always discuss your personalized cancer treatment strategy and symptom management directly with your radiation oncologist.
Does rs1801516 increase my risk of developing cancer?
Large meta-analyses evaluating cancer susceptibility have found no consistent or significant overall association between rs1801516 and cancer occurrence. While rare, truncating mutations in ATM clearly predispose to certain malignancies like breast cancer, common variants such as rs1801516 do not carry the same clinical significance.
Can routine diagnostic X-rays or CT scans harm someone with this variant?
No evidence suggests that diagnostic imaging delivers enough radiation to trigger meaningful complications associated with rs1801516. The modest toxicity correlations identified in scientific studies involve concentrated, high-dose therapeutic radiation regimens rather than low-dose diagnostic scans.
Sources & further reading
Educational information only, last refreshed 9/5/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1801516?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29